The AGENT™ Drug-Coated Balloon (DCB) makes reliable drug transfer more deliverable. AGENT is unlike other DCBs on the market. It builds on the proven balloon innovation and powerful efficient drug eluting technology by Boston Scientific that you know and trust.

AGENT is the first and only U.S. coronary drug-coated balloon (DCB), introducing a new treatment option for patients with in-stent restenosis (ISR). AGENT is purposefully designed to provide reliable and efficient drug transfer, and effortless deliverability in complex anatomy.</p>

Boston Scientific's Ranger Drug-Coated Balloon is built on the physician preferred Sterling™ 0.014”/0.018” balloon platform¹ with the lowest tip entry profile of any SFA DCB². For ease, durability and effectiveness, Ranger DCB delivers like nothing else. Two Randomized Controlled DCB Trials. Zero doubt.

The AGENTTM Paclitaxel-Coated Balloon Catheter (hereafter referred to as AGENT Drug-Coated Balloon (DCB), AGENT Balloon Catheter, or AGENT DCB) is a monorail, semi-compliant...

2023年10月25日 · This trial met the primary endpoint of target lesion failure 4 (TLF) at 12 months with the AGENT DCB demonstrating statistical superiority to uncoated balloon angioplasty (17.9% vs. 28.7%; P=0.006). These differences were mainly driven by significantly reduced rates of myocardial infarction related to the target vessel (TV-MI, or heart attack ...

2023年10月25日 · MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal AGENT IDE clinical trial of...

MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™...

October 30, 2023 — Boston Scientific Corporation on Friday announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENT Drug-Coated Balloon (DCB).1 Primary endpoint findings from this first clinical trial in the U.S. to evaluate the safety and effectiveness of using a DCB to treat coronary in-stent restenosis ...

2020年6月22日 · Drug-coated balloons (DCBs) are a novel treatment strategy for coronary artery disease based on the fast and homogenous transfer of antiproliferative drugs into the vessel wall during single balloon inflation by means of a lipophilic matrix without the use of permanent implants (Figure 1).

Ranger is a low dose DCB with a uniquely formulated TransPax coating that results in highly efficient drug transfer. This enables extremely targeted drug delivery, achieving nearly 90% primary patency 1 , with the least amount of downstream particulates 4 and low systemic drug exposure to the patient. 5